Description

The Reimbursement Coding and Strategy Director leads the development and execution of U.S. coding strategies for new and existing in vitro diagnostic products. The role assesses coding pathways and gaps, defines evidence and documentation requirements, and integrates coding considerations into product development, launch readiness, and lifecycle planning. Working cross-functionally with Market Access, Medical Affairs, Regulatory Affairs, HEOR, Marketing, Government Affairs, and global teams. Alongside working with VP Market Access North America, this position translates complex coding requirements into clear recommendations, implementation plans, and customer-facing resources. The role serves as the organization’s subject-matter expert for diagnostic coding strategy and monitors changes that may affect product access, reimbursement, and commercial execution.

Position Duties

Coding Strategy and Pathway Development

Lead the development of U.S. coding strategies for pipeline, launch, and on-market diagnostic products.
Assess available coding pathways, including CPT, PLA, HCPCS, and ICD-10 considerations, and recommend the pathway that best supports the intended use, site of service, and reimbursement objective.
Identify coding gaps, risks, dependencies, and decision points early in product development and translate findings into actionable recommendations for governance and product teams.
Develop long-range coding roadmaps, including key milestones, evidence needs, submission timing, ownership, and contingency approaches.
Evaluate when existing codes may be appropriate and when a new or revised code may be needed, documenting the rationale, business impact, and implementation considerations.
Adjust coding strategies for existing products in response to product changes, utilization patterns, coding updates, or reimbursement barriers.

Coding Applications, Evidence, and Documentation

Lead or coordinate the preparation of coding applications, supporting narratives, technical documentation, and evidence packages in partnership with Government Affairs, Medical Affairs, Regulatory Affairs, HEOR, and other subject-matter experts.
Define the clinical, technical, utilization, and economic evidence needed to support coding objectives and incorporate those requirements into evidence-generation plans.
Ensure coding submissions and supporting materials accurately reflect product characteristics, intended use, clinical utility, and the applicable diagnostic pathway.
Maintain a centralized record of coding decisions, assumptions, submission history, status, risks, and outcomes to support continuity and organizational learning.
Coordinate internal review and approval of coding materials in accordance with company requirements and applicable standards.
Represents and attends the following: AMA, ADLM, ACLA, CAP, AMP

Product Development and Launch Integration

Represent Market Access and coding strategy in U.S. go-to-market, pipeline, and lifecycle governance processes.
Integrate coding considerations into product profiles, evidence plans, launch sequencing, pricing and reimbursement planning, and commercial readiness activities.
Provide U.S. coding insights to global teams and adapt global market access tools to address U.S. coding requirements.
Partner with brand and commercial teams to develop coding-related launch plans, customer resources, internal training, and objection-handling tools.
Assess the operational implications of coding decisions for laboratories, providers, revenue cycle teams, sales teams, and customer support functions.

Coding Intelligence, Governance, and Enablement

Monitor coding publications, code-set updates, application cycles, and industry developments that may affect pipeline or on-market products.
Analyze potential business and access impact, communicate findings to relevant stakeholders, and recommend response plans.
Establish coding governance tools, decision frameworks, standard operating practices, and performance measures to improve consistency and execution.
Develop and maintain approved coding guides, reimbursement resources, training materials, and internal reference tools.
Serve as an internal expert and educator on diagnostic coding concepts, pathways, limitations, and appropriate use of coding information.
Collect field and customer insights related to coding barriers and use those insights to refine product-level strategies and close access gaps.
Perform all work in compliance with company quality procedures and standards.
Perform other duties as assigned.

Qualifications

Education and Training

Bachelor's degree in Health Policy, Political Science, Life Sciences, Law, Public Health, Economics, or Business.
Advanced degree preferred (e.g., MBA, MPH).

Experience

7+ years of healthcare experience in clinical laboratory, pharmaceutical, and/or biotechnology industries.
3+ years of Medicare Policy experience with experience of the U.S. healthcare policy and market access landscape.

Preferred:

Diagnostic or Medical Devices experience preferred, along with familiarity with diagnostic technologies utilized in the laboratory setting, regulatory impacts, commercialization, and reimbursement considerations.

Knowledge, Skills, and Abilities (KSAs)

Proven track record in building relationships and advocating for policy changes.
Must demonstrate strong strategy, innovation, collaboration, and analytical skills.
A strong communicator that can lead delivery and creation of innovative and tailored communications to educate and mobilize critical stakeholders is required.
Deep understanding of the US Market Access environment (e.g., U.S. payer system, coding, payment, coverage and stakeholder engagement).
Demonstrated ability to work both independently and interdependently in cross-functional (matrix) teams.
Proactive, self-motivated, and aware of larger business needs/implications.
Must be capable of prioritizing multiple priorities, model leadership behaviors, and create partnership across functions.
Possess the highest standards of ethics and integrity.

Working Conditions

Ability to remain in stationary position, often standing, for prolonged periods.
Ability to ascend/descend stairs, ladders, ramps, and the like.
Domestic Travel Required: 20%.
International Travel Required: 0%.

The estimated salary range for this role based in the Field is between $170,000 – $269,800. This role is eligible to receive a variable annual bonus based on company, team, and individual performance per bioMerieux’s bonus program. This range may differ from ranges offered for similar positions elsewhere in the country given differences in cost of living. Actual compensation within this range is determined based on the successful candidate’s experience and will be presented in writing at the time of the offer.

In addition, bioMérieux offers a competitive Total Rewards package that may include:

·A choice of medical (including prescription), dental, and vision plans providing nationwide coverage and telemedicine options

·Company-Provided Life and Accidental Death Insurance

·Short and Long-Term Disability Insurance

·Retirement Plan including a generous non-discretionary employer contribution and employer match.

·Adoption Assistance

·Wellness Programs

·Employee Assistance Program

·Commuter Benefits

·Various voluntary benefit offerings

·Discount programs

·Parental leaves

#biojobs

#LI-AG1

Please be aware that recruitment related scams are on the rise. Fraudulent job postings are being placed on other websites, and individuals posing as bioMérieux Talent Acquisition team members are reaching out via email or text message in an attempt to collect your personal and confidential information. In some cases, these scammers are also conducting bogus interviews prior to extending fraudulent offers of employment. Beware of individuals reaching out using general phone numbers and non-bioMerieux email domains (i.e. Hotmail.com, Gmail.com, Yahoo.com, etc.). If you are concerned that an interview experience or offer of employment might be a scam, please make sure you are searching for the posting on our careers site https://careers.biomerieux.com/ or contact us at [email protected].

BioMérieux Inc. and its affiliates are Equal Opportunity/Affirmative Action Employers. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, age, protected veteran or disabled status, or genetic information. Please be advised that the receipt of satisfactory responses to reference requests and the provision of satisfactory proof of an applicant’s identity and legal authorization to work in the United States are required of all new hires. Any misrepresentation, falsification, or material omission may result in the failure to receive an offer, the retraction of an offer, or if already hired, dismissal. If you are a qualified individual with a disability, you may request a reasonable accommodation in BioMérieux’s or its affiliates’ application process by contacting us via telephone at (385) 770-1132, by email at [email protected], or by dialing 711 for access to Telecommunications Relay Services (TRS).

About the company

bioMérieux provides medical diagnostics worldwide by developing, manufacturing, and selling diagnostic tests, instruments, and software that detect infectious diseases and antimicrobial resistance. Its products work by analyzing patient samples through diagnostic assays and integrated systems that combine reagents, specialized instruments, and software to produce actionable test results for healthcare providers, laboratories, and public health agencies. The company stands out from competitors through its global leadership in in vitro diagnostics, a broad portfolio of instruments, reagents, and software, and a strong emphasis on public health and antimicrobial resistance challenges. Its goal is to improve patient care and public health by delivering timely, accurate diagnoses that help guide treatment and curb the spread of infectious diseases.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Marcy-l'Étoile, France

Founded

1963

Get referred to bioMérieux

See people who can refer or advise you

Simplify's Take

What believers are saying

September 24, 2026 SPINCHIP launch opens a new European point-of-care franchise.
May 29, 2026 France factory adds BIOFIRE capacity and 400 jobs by 2030.
June 18, 2026 GENE-UP TYPER SLM expands food-safety testing into Salmonella root-cause analysis.

What critics are saying

December 2025 San José closure shows portfolio pruning and execution risk.
Lyme disease appeal awaited mid-March 2026 keeps litigation overhang alive.
2026 guidance was cut, and GO•28 targets were reset lower, pressuring valuation.

What makes bioMérieux unique

BIOFIRE syndromic PCR spans respiratory, bloodstream, gastrointestinal, and meningitis testing.
SPINCHIP gives bioMérieux laboratory-grade troponin results at the point of care.
Industrial diagnostics and pharma QC diversify revenue beyond hospital microbiology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Adoption Assistance
Wellness Program
Employee Assistance Program
Commuter Benefits
Parental Leave

Company News

bioMérieux

Sep 24th, 2026

bioMérieux launches SPINCHIP(R) hs-cTnl, a major innovation for the measurement of high-sensitivity cardiac troponin I and faster management of cardiac emergencies.

bioMérieux launches SPINCHIP(R) hs-cTnl, a major innovation for the measurement of high-sensitivity cardiac troponin I and faster management of cardiac emergencies. Marcy-l'Étoile (France), September 24, 2026 - bioMérieux, a global leader in in vitro diagnostics, today announced the launch of SPINCHIP(R), an innovative point-of-care platform, featuring its first test for the measurement of high-sensitivity cardiac troponin I from a single drop of blood: SPINCHIP(R) hs-cTnl. Presented at the European Society of Emergency Medicine (EUSEM) Congress in Paris, this rapid diagnostic solution will initially be available in Europe, bringing a critical test closer to the point of care and helping emergency teams quickly triage adult patients with suspected acute myocardial infarction. Overcrowding in Emergency Departments and patient prioritization: A societal challenge for healthcare efficiency. Across Europe, emergency departments are facing increasing pressure, with direct consequences for the quality of care, response times, team organization, and the use of hospital resources. A study conducted by EUSEM in 2023 reveals that approximately 90% of emergency department professionals in Europe believe their department regularly faces a patient volume that exceeds its capacity to provide care.[1] According to several national studies, chest pain is estimated to account for approximatively 5 to 10 percent of adult presentations in European emergency departments.2 In traditional care pathways, the assessment of the risk of myocardial infarction relies on troponin testing performed by the hospital laboratory. However, the average wait time between sample collection and the return of results is approximately one hour and 30 minutes.3 This delay may slow down medical decision-making and put the patient's health at risk. It may also unnecessarily prolong patients' stays in the emergency department and limit bed availability. "In the emergency department, when a patient presents with chest pain, time counts, and uncertainty becomes a major risk factor. Waiting more than an hour for lab results creates a bottleneck, putting a strain on departments, with direct impacts on patient management and cost of care. Today, there is a significant need for rapid and reliable diagnostic results as close to the patient as possible, directly in the emergency departments," emphasizes Prof. Helge Røsjø, Scientific Leader of Akershus Clinical Research Center and Head of Research & Innovation at Akershus University Hospital in Norway. SPINCHIP(R): bringing laboratory-grade performance to the point of care. bioMérieux is launching SPINCHIP(R), a compact immunoassay platform for point-of-care testing outside traditional laboratories. Its first test, SPINCHIP(R) hs-cTnI, enables high-sensitivity measurement of the cardiac marker troponin I to accelerate clinical decision-making, allowing for rapid and confident triage of adult patients with suspected acute myocardial infarction. With a turnaround time of around 10 minutes, SPINCHIP(R) speeds up patient triage, helping streamline care pathways, relieve pressure on emergency departments, and optimize the use of hospital resources. The technology is based on a test capable of providing a highly accurate result from a single drop of capillary blood - a major advantage for both patient comfort and ease of use. The platform can be used by all emergency care professionals while offering analytical performance comparable to that of laboratory instruments. Its intuitive operation consists of three steps: collecting a drop of blood from the fingertip using a cartridge barely larger than a coin, inserting the cartridge into the device, and reading the result after 10 minutes. The SPINCHIP(R) solution is designed to connect to hospital information systems to facilitate traceability and the integration of results into the patient's care pathway, under the supervision of clinical laboratory scientists. A strategic launch for bioMérieux. "With SPINCHIP(R), we're bringing our long-standing expertise in immunoassays directly to emergency departments, closer to the patient. This innovation reflects our ongoing commitment to point-of-care testing: to help improve patient care while assisting healthcare systems in better organizing their resources," said Pierre Boulud, CEO of bioMérieux. One year after acquiring the Norwegian company SpinChip Diagnostics, bioMérieux is taking a new step forward in the development of its point-of-care testing portfolio. The SPINCHIP(R) solution, which is part of the company's GO - 28 strategic plan, will contribute to bioMérieux's long-term growth, well beyond 2028. Officially CE-marked in accordance with the IVDR* regulation, the SPINCHIP(R) hs-cTnl test is initially being launched in Europe, before a gradual rollout outside the European Union. [2] France: Panorama des Observatoires Régionaux des Urgences - FEDORU (2025)3 Gobeaux C et al.French laboratories turn-around-time (TAT) for troponin measurement for Emergency Departments: the EN-TRO-PRISE survey. Ann Biol Clin (Paris). 2025 Jun 1;83(3):293-302. United Kingdom: Goodacre S, Cross E, Arnold J, Angelini K, Capewell S, Nicholl J. The health care burden of acute chest pain. Heart. 2005 Feb;91(2):229-30. doi: 10.1136/hrt.2003.027599. PMID: 15657244; PMCID: PMC1768669. Spain: Bragulat Ernest, López Beatriz, Miró Óscar, Coll-Vinent Blanca, Jiménez Sonia, Aparicio María J, Heras Magda, Bosch Xavier, Valls Valentí, Sánchez Miquel Performance Assessment of an Emergency Department Chest Pain Unit, Revista Española de Cardiología (English Edition), ISSN 18855857, https://doi.org/10.1016/S1885-5857(07)60152-2, https://www.revespcardiol.orghttps://www.revespcardiol.org/en-performance-assessment-of-an-emergency-d-articulo-13100644. Sweden: Henricson J, Ekelund U, Hartman J, Ziegler B, Kurland L, Björk Wilhelms D. Pathways to the emergency department - a national, cross-sectional study in Sweden. BMC Emerg Med. 2022 Apr 7;22(1):58. doi: 10.1186/s12873-022-00619-3. PMID: 35392826; PMCID: PMC8991881. [3] Gobeaux C et al.French laboratories turn-around-time (TAT) for troponin measurement for Emergency Departments: the EN-TRO-PRISE survey. Ann Biol Clin (Paris). 2025 Jun 1;83(3):293-302. * In Vitro Diagnostic Regulation.

NTB

Sep 18th, 2026

SpinChip Diagnostics to be Acquired by bioMérieux | SpinChip Diagnostics ASA

Transaction Valuation: SpinChip valued at NOK 1,624 million (EUR 138 million), making it one of the largest MedTech transactions in Norway. Menu Development: bioMérieux will accelerate the menu build-up of SpinChip’s Point of Care diagnostics platform. Strategic Growth: bioMérieux strengthens its position in the Point of Care market. Oslo, Norway, 13 January 2025 — SpinChip Diagnostics ASA (“SpinChip”), an innovative diagnostics company developing next-generation Point of Care platforms for in vitro diagnostics, announces its agreement to be acquired by bioMérieux, a global leader in in vitro diagnostics. Under the agreement, bioMérieux will acquire 100% ownership of SpinChip for a Total Enterprise Value of NOK 1,624 million. Morten Jurs, Chief Executive Officer of SpinChip, stated: “The dedication of the SpinChip team over the past decade has been exceptional. Their relentless efforts have led to the development of a groundbreaking diagnostics platform that has the potential to signif

JSAN Publication

Aug 19th, 2026

Who owns Moderna right now in 2026?

Who owns Moderna right now in 2026? Moderna is publicly traded and widely held, not controlled by a family, state, or private equity sponsor. That makes who owns Moderna easier to see in filings, and it keeps control tied to the market rather than a single block holder. Moderna trades on the NASDAQ stock exchange under the ticker symbol MRNA and is a component of the S&P 500 index. The largest individual insider shareholders of Moderna are Stéphane Bancel (CEO) with approximately 7.3%, Noubar Afeyan (Co-founder and Chairman) with approximately 5%, Robert S. Langer (Co-founder) with approximately 4%, and Stephen Hoge (President) with approximately 1.3%. On the institutional side, the largest institutional shareholders of Moderna include Vanguard Group Inc., BlackRock, Inc., FMR LLC (Fidelity), Baillie Gifford & Co., State Street Corp., Capital World Investors, Geode Capital Management, and Morgan Stanley. No single person or entity controls Moderna outright. It is a widely distributed public company where the biggest voices are large index funds and asset managers - the same institutional giants that dominate most large American public companies. Ownership and key stakeholders table. The origin story: A conversation that changed medicine. Moderna was founded in 2010 by Noubar Afeyan, founder and CEO of Flagship Pioneering, in collaboration with Robert Langer, a professor of chemical engineering at MIT, and Derrick Rossi, a stem cell biologist, with the aim of developing messenger RNA (mRNA) therapeutics as a novel drug modality. The company originated from exploratory work within Flagship's VentureLabs, initially codenamed LS18, and was renamed Moderna Therapeutics to reflect its focus on modified RNA technologies. The spark was a meeting between Noubar Afeyan and Derrick Rossi, who had been doing breakthrough research on using chemically modified mRNA to reprogram cells. Noubar Afeyan met with Bob Langer and Derrick Rossi to review recent data on the use of chemically modified mRNA to reprogram adult human fibroblast cells into induced pluripotent stem cells. Noubar envisioned a different use of engineered mRNA as a new kind of medicine and launched within Flagship's VentureLabs group a month-long exploration which eventually led to Newco LS18, Inc. - which became Moderna. Stéphane Bancel, who had been Chief Executive Officer of the French diagnostics company bioMérieux SA, joined Moderna's board of directors in March 2011, and became its CEO in October 2011. Bancel was the operational genius who took a brilliant scientific idea and turned it into a scalable company. Under his leadership, Moderna secured partnerships, built laboratories, raised hundreds of millions of dollars, and survived years of skepticism from the broader scientific and investment community - many of whom believed mRNA medicine was too speculative to ever work. The COVID-19 moment that changed everything. For its first decade, Moderna was known only within the biotechnology world. Then came 2020 - and everything changed overnight. When SARS-CoV-2 emerged in early 2020, Moderna's scientists began designing a vaccine within days of the viral genome being published. The mRNA platform they had spent a decade building was perfectly suited for the task - because instead of growing virus in a lab to make a traditional vaccine, Moderna just needed to encode the spike protein instructions into mRNA and inject them. Moderna received an award from U.S. government agency BARDA for up to $483 million to accelerate development. It then announced a supply agreement with the U.S. government for an initial 100 million doses of its COVID-19 vaccine. The result was Spikevax - one of the first two mRNA COVID-19 vaccines in history - which achieved 94.5% efficacy in clinical trials and was authorized for emergency use by the FDA in December 2020. Almost overnight, Moderna went from a well-funded biotech startup to one of the most important companies in the world. The IPO and the Road to the S&P 500. Moderna became a public company through its 2018 IPO, which opened the cap table to public investors and shifted control from founders to shareholders. At the time of its IPO, Moderna had never had a single approved product. It went public purely on the strength of its mRNA platform and pipeline - an extraordinary level of investor conviction. The 2018 IPO raised approximately $600 million - the largest biotech IPO in history at that time. The underwriters priced shares at $23 each. By the peak of the COVID-19 vaccine rollout in 2021, MRNA shares had hit $497 - a gain of more than 2,000% in under three years. That surge created enormous paper wealth for the founders. Stéphane Bancel's net worth briefly exceeded $10 billion at the peak. Noubar Afeyan and Robert Langer also saw their stakes become worth billions. The Moderna story had become one of the greatest wealth-creation events in biotechnology history. Where is Moderna today in 2026? The post-COVID world has been a harder one for Moderna. Demand for COVID-19 vaccines has normalized dramatically, and the company has posted significant losses as it works to build out its broader pipeline. Moderna reported revenue of $1.94 billion in 2025, with a net loss of $2.8 billion and total assets of $12.3 billion. The company employs approximately 4,800 people. But Moderna's pipeline tells a more optimistic story. The company is advancing mRNA-based cancer vaccines - personalized treatments designed specifically for an individual patient's tumor - and has reported promising early results in trials with Merck. CEO Stéphane Bancel stated in early 2026: "I believe 2026 will also be the year when the world sees the promise of Moderna as a leading oncology company." In August 2026, the FDA approved Moderna's new mRNA-based flu vaccine - the first mRNA flu shot available to the public - marking another major milestone in the company's mission to use mRNA to fight a wide range of diseases beyond COVID-19. Frequently asked questions (faqs). Q1. Who owns Moderna in 2026? Moderna (NASDAQ: MRNA) is publicly owned with no single controlling shareholder - Vanguard and BlackRock are the largest institutional holders. Q2. Who founded Moderna? Moderna was founded in September 2010 by Noubar Afeyan, Robert Langer, Derrick Rossi, Kenneth Chien, and Timothy Springer, backed by Flagship Pioneering. Q3. Who is the CEO of Moderna in 2026? Stéphane Bancel is the CEO of Moderna, a role he has held since October 2011 after being recruited by co-founder Noubar Afeyan. Q4. What percentage of Moderna does Stéphane Bancel own? Stéphane Bancel owns approximately 7.3% of Moderna, making him the largest individual insider shareholder. Q5. When did Moderna go public? Moderna held its IPO in December 2018 on NASDAQ, pricing shares at $23 - the largest biotech IPO in history at that time. Q6. What is Moderna's revenue in 2025? Moderna reported $1.94 billion in revenue for 2025, with a net loss of $2.8 billion as it funds its broader pipeline beyond COVID-19 vaccines. Q7. Does the U.S. government own part of Moderna? No. The U.S. government funded Moderna's COVID-19 vaccine development through BARDA grants and supply agreements but holds no equity ownership in the company. Q8. What new products is Moderna launching in 2026? In August 2026, the FDA approved Moderna's first mRNA-based flu vaccine - and the company is advancing personalized mRNA cancer vaccines in partnership with Merck. Moderna is a publicly traded company on NASDAQ (ticker: MRNA) with no single controlling owner. It was founded in September 2010 by Noubar Afeyan, Robert Langer, Derrick Rossi, Kenneth Chien, and Timothy Springer - backed from day one by Flagship Pioneering, the venture capital firm that incubated the entire concept. The largest individual insider shareholders today are CEO Stéphane Bancel (~7.3%), Co-founder and Chairman Noubar Afeyan (~5%), and Co-founder Robert Langer (~4%). The biggest institutional holders are Vanguard, BlackRock, Fidelity, and Baillie Gifford. No single entity holds majority control - making Moderna a true public company, accountable to its broad shareholder base. From a codenamed startup experiment in 2010 to a COVID-19 vaccine that reached hundreds of millions of people, to an mRNA flu shot approved by the FDA in 2026 - Moderna's story is far from over.

PR Newswire

Aug 7th, 2026

bioMérieux highlights positive impacts of rapid, accurate diagnostics for Patients and accepts industry awards at ADLM 2026.

bioMérieux highlights positive impacts of rapid, accurate diagnostics for Patients and accepts industry awards at ADLM 2026. Aug 07, 2026, 14:10 ET SALT LAKE CITY, Aug. 7, 2026 /PRNewswire/ - bioMérieux, a world leader in the field of in vitro diagnostics, leveraged this year's 2026 Association for Diagnostics & Laboratory Medicine (ADLM) Annual Conference & Clinical Lab Expo for an important conversation about the impact of access to diagnostics while also accepting multiple IMV ServiceTrak(TM) awards. PRESS CONFERENCE The company hosted a press panel, The Power of Diagnostics: How Delays Impact Patients and Providers, to discuss the real-world impacts of delayed or inaccurate diagnostic answers for patients, providers, communities, and the healthcare system. Dr. Charles K. Cooper, Executive Vice President and Chief Medical Officer at bioMérieux, moderated the panel with: * Dr. Omai Garner, Clinical Professor and Director of Clinical Microbiology, UCLA; * Dr. Michael Astion, PhD, Medical Director, Regional Laboratories and Point of Care, Medical Director, Reference Laboratories and PLUGS (Patient-Centered Laboratory Utilization Guidance Services), Department of Laboratories, Seattle Children's Hospital, Professor of Laboratory Medicine and Pathology, University of Washington; * Helaine Bader, MPH Vice President of Education, HealthyWomen; and * Dr. John Hurst, Senior Director, Field Medical Affairs at bioMérieux. Dr. Cooper noted that the panel discussed the "tremendous amount of pressure health care systems face and how access to rapid diagnostics at the point of care often alleviates some of this stress by getting health care clinicians and their patients answers while they wait." "Delay in getting a diagnosis may result in patients not receiving treatment at all because they may not come back for follow-up," said Ms. Bader. "Faster time to diagnosis during a single visit not only provides the patient with immediate answers but also builds trust between the patient and provider and reduces patient frustration, potential complications from the infection and the need for repeat visits." INDUSTRY RECOGNITION During the show, bioMérieux also accepted seven 2026 IMV ServiceTrak(TM) Clinical Laboratory Awards. These awards highlight bioMérieux's continued commitment to delivering industry-leading diagnostic solutions and exceptional customer support to clinical laboratories. 2026 ServiceTrak Awards: ID/AST Systems * Best Customer Satisfaction * Best System Performance * Best Service 2026 ServiceTrak Awards: Blood Culture Systems * Best Customer Satisfaction * Best System Performance * Best Service 2026 Best System Performance * Immunoassay Analyzers "We are thrilled that IMV and the Science and Medicine Group has recognized bioMérieux for the ninth consecutive year for the continued dedication and excellence of our product management, operations, and customer support teams," said Randy Pritchard, General Manager and Sr. Vice President of Clinical Operations, bioMérieux. "This recognition, across our immunoassay, ID/AST Systems, and Blood Culture Systems offerings, highlights our commitment to pioneering diagnostics in the fight against sepsis and antimicrobial resistance." ABOUT BIOMÉRIEUX Pioneering Diagnostics A world leader in the field of in vitro diagnostics since 1963, bioMérieux is present in 46 countries and serves more than 160 countries with the support of a large network of distributors. In 2025, revenues reached €4.1 billion, with over 94% of sales outside of France. bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. www.biomerieux.com. bioMérieux is listed on the Euronext Paris stock market. Symbol: BIM - ISIN Code: FR0013280286 Reuters: BIOX.PA/Bloomberg: BIM.FP SOURCE bioMérieux

Ashland - Local Town Pages

Jul 14th, 2026

bioMérieux to Showcase Company's Latest in Diagnostic Innovations at ADLM 2026.

bioMérieux to Showcase Company's Latest in Diagnostic Innovations at ADLM 2026. PR Newswire Today at 8:43am PDT ANAHEIM, Calif., July 14, 2026 /PRNewswire/ - bioMérieux, a global leader in in vitro diagnostics, today announced it will showcase its latest diagnostic solutions and innovations at the 2026 Association for Diagnostics & Laboratory Medicine (ADLM) Annual Conference & Clinical Lab Expo, taking place in Anaheim, California, July 26 through 30. Attendees are invited to visit bioMérieux at booth #2501 in Hall B to explore the company's comprehensive portfolio and connect with experts across clinical microbiology, molecular diagnostics, and laboratory informatics. Featured Technologies at Booth #2501 This year's company presence is anchored by the theme: "A legacy of diagnostic leadership. Your partner for what's ahead." The theme reflects bioMérieux's continued commitment to advancing diagnostic excellence over the past 63 years, while supporting laboratories and healthcare practitioners in navigating the future of medicine. At the expo, bioMérieux will highlight a range of innovative platforms designed to showcase the company's end-to-end laboratory ecosystem including: BIOFIRE(R) FILMARRAY(R) TORCH System, a multiplex PCR technology that tests for a comprehensive group of targets in about an hour, BIOFIRE(R) SPOTFIRE(R) System, a multiplex PCR platform that brings reliable diagnostics to point-of-care clinical settings, VITEK(R) MS PRIME, a mass spectrometry system for routine microbial identification, and the VIDAS(R) 3, an automated benchtop immunoassay system. Visitors will be able to explore how bioMérieux's solutions connect microbiology, molecular diagnostics, laboratory automation, informatics, and stewardship initiatives to help laboratories improve efficiency, accelerate decision-making, and optimize patient care. In addition, visitors can explore bioMérieux's latest data and IT solutions, and Lab Consultancy offerings, designed to help laboratories optimize operations, improve outcomes, and drive digital transformation. Educational Symposiums As part of its commitment to advancing clinical knowledge and best practices, and demonstrating the value of diagnostics, bioMérieux will host two symposiums included in the conference's agenda: * From Central Lab to POC: Rethinking Vaginitis Diagnostics * Tuesday, July 28 from 12:00 p.m. until 12:20 p.m. in Exhibit Hall Theater 2 * Attendees will examine current diagnostic limitations, the consequences of delayed results, and how point-of-care testing aligns with real-time decision making. * The Syndromic Standard: Explore the Clinical Impact of MPCR GI Panels for Gastroenteritis * Tuesday, July 28 from 2:45 p.m. until 3:35 p.m. in Exhibit Hall Theater 1 * Attendees will learn about the latest developments in reducing diagnostic uncertainty, improving time-to-treatment, and advancing patient outcomes. Press Conference and Panel Discussion The company will also host a press conference panel, The Power of Diagnostics: How Delays Impact Patients and Providers, on Wednesday, July 29 from 9:00 a.m. until 9:45 a.m. in room 213D. Panel experts from bioMérieux, rural medicine, and patient advocacy will discuss the real-world impacts of delayed or inaccurate diagnostic answers for patients, providers, communities, and the healthcare system, especially as they affect women, minority communities, and other underserved populations. The panel will feature real-world examples from patient and provider experiences and potential solutions for today and the future. Conference attendees and members of the media are invited to attend. For media looking to register for event credentials: visit https://myadlm.org/media/press-registration. For more information on the bioMérieux press conference contact: [email protected]. ABOUT BIOMÉRIEUX Pioneering Diagnostics A world leader in the field of in vitro diagnostics since 1963, bioMérieux is present in 46 countries and serves more than 160 countries with the support of a large network of distributors. In 2025, revenues reached €4.1 billion, with over 94% of sales outside of France. bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. bioMérieux is listed on the Euronext Paris stock market. Symbol: BIM - ISIN Code: FR0013280286 Reuters: BIOX.PA/Bloomberg: BIM.FP SOURCE bioMerieux This is a paid placement. For further inquiries, please contact PR Newswire directly.